Article Information
History
- March 24, 2022.
Article Versions
- Version 1 (April 30, 2021 - 16:25).
- Version 2 (May 3, 2021 - 13:55).
- Version 3 (May 4, 2021 - 10:19).
- Version 4 (September 9, 2021 - 11:01).
- Version 5 (January 7, 2022 - 09:12).
- You are viewing Version 6, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Kathryn Westendorf1,‡,
- Stefanie Žentelis1,‡,
- Lingshu Wang2,
- Denisa Foster3,
- Peter Vaillancourt3,
- Matthew Wiggin1,
- Erica Lovett1,
- Robin van der Lee1,
- Jörg Hendle3,
- Anna Pustilnik3,
- J. Michael Sauder3,
- Lucas Kraft1,
- Yuri Hwang1,
- Robert W. Siegel4,
- Jinbiao Chen4,
- Beverly A. Heinz4,
- Richard E. Higgs4,
- Nicole L. Kallewaard4,
- Kevin Jepson1,
- Rodrigo Goya1,
- Maia A. Smith1,
- David W. Collins1,
- Davide Pellacani1,
- Ping Xiang1,
- Valentine de Puyraimond1,
- Marketa Ricicova1,
- Lindsay Devorkin1,
- Caitlin Pritchard1,
- Aoise O’Neill1,
- Kush Dalal1,
- Pankaj Panwar1,
- Harveer Dhupar1,
- Fabian A. Garces1,
- Courtney A. Cohen5,
- John M. Dye5,
- Kathleen E. Huie5,
- Catherine V. Badger5,
- Darwyn Kobasa6,7,
- Jonathan Audet6,7,
- Joshua J. Freitas3,
- Saleema Hassanali3,
- Ina Hughes3,
- Luis Munoz3,
- Holly C. Palma3,
- Bharathi Ramamurthy3,
- Robert W. Cross7,8,
- Thomas W. Geisbert7,8,
- Vineet Menacherry8,
- Kumari Lokugamage8,
- Viktoriya Borisevich8,
- Iliana Lanz1,
- Lisa Anderson1,
- Payal Sipahimalani1,
- Kizzmekia S. Corbett2,
- Eun Sung Yang2,
- Yi Zhang2,
- Wei Shi2,
- Tongqing Zhou2,
- Misook Choe2,
- John Misasi2,
- Peter D. Kwong2,
- Nancy J. Sullivan2,
- Barney S. Graham2,
- Tara L. Fernandez1,
- Carl L. Hansen1,
- Ester Falconer1,
- John R. Mascola2,
- Bryan E. Jones3,* and
- Bryan C. Barnhart1,*
- 1AbCellera Biologics Inc., Vancouver, BC, Canada
- 2Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
- 3Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA, USA
- 4Eli Lilly and Company, Indianapolis, IN, USA
- 5U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD, 21702, USA
- 6National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
- 7University of Manitoba, Winnipeg, Manitoba, Canada
- 8Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, 77555, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, 77555, USA
- ↵*Corresponding author: bo.barnhart{at}abcellera.com, jones_bryan_edward{at}lilly.com
↵‡ Authors contributed equally